Skip to main content

Table 4 The mortality of DTC survivors developing SMs by different sites

From: Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

 

overall mortality

disease specific mortality

with RAI

no RAI

P value

with RAI

no RAI

P value

All cancer combined

25.5%

28.0%

0.001

16.4%

18.3%

0.081

Oral Cavity and Pharynx

26.8%

23.5%

0.008

7.1%

3.9%

0.681

Digestive System

39.5%

47.2%

0.052

32.3%

36.8%

0.225

Respiratory System

62.3%

61.0%

0.783

47.8%

49.2%

0.789

Skin

12.3%

11.7%

1.000

5.1%

2.9%

0.54

Breast

9.9%

11.0%

0.559

4.8%

5.9%

0.427

Female Genital System

20.1%

22.8%

0.537

14.5%

19.4%

0.224

Male Genital System

8.4%

9.0%

0.871

3.4%

3.4%

1.000

Urinary System

17.5%

19.9%

0.602

10.3%

8.9%

0.73

Nervous System

63.3%

66.7%

0.801

60.0%

63.9%

0.802

Hematopoietic System

25.7%

29.3%

0.409

17.2%

20.9%

0.347